Search results
Showing 8881 to 8895 of 8899 results
Learn more about the proposed changes to our routing criteria for highly specialised technologies
Home News Podcasts Learn more about the proposed changes to our routing criteria for highly specialised technologies Podcasts 31 December 2024
Additional evidence needed to assess histology-independent cancer drugs
A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.
NICE and NIHR: working together to produce research with impact
Alice and Zoe discuss how the National Institute of Health Research (NIHR) and NICE work in partnership and identify key research priorities from NICE guidance.
Dr Roberts, who is a qualified doctor, has 20 years’ experience in clinical and management posts in healthcare both in the private and public sector.
Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
Patient safety and surgical innovation – why new isn't always better
Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.
Children and young people set to benefit from new treatment for peanut allergy
Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.
Putting user needs at the heart of an advisory service for AI and data-driven technologies
Toni Gasse explains how user-needs are being placed front and centre to develop a multi-agency advisory service for artificial intelligence and data-driven technologies.
Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
25 years of NICE and focusing on what matters most to deliver for the future
Home News Podcasts 25 years of NICE and focusing on what matters most to deliver for the future Podcasts 01 May 2024 Listen About this episode
Home News Podcasts Assessing the familial and genetic risk of ovarian cancer Podcasts 03 April 2024 Listen About this episode We talk to Ranjit
Learn more about the NICE and NHS England MedTech Pathway consultation
Home News Podcasts Learn more about the NICE and NHS England MedTech Pathway consultation Podcasts 03 June 2024 Listen About this episode
Learn more about NICE's new guideline on identifying and managing adrenal insufficiency
Home News Podcasts Learn more about NICE's new guideline on identifying and managing adrenal insufficiency Podcasts 29 August 2024 Listen